Good news from the clinic -- albeit one far from the U.S. -- was the factor pushing up Bristol Myers Squibb (NYSE:BMY) stock on Monday. Shares of the global pharmaceutical company inched marginally higher amid positive data from an experimental cancer drug. That's the latest step in Bristol Myers Squibb's long journey to move from dependence on its legacy medications to its so-called "growth portfolio." If that new medication, which it didn't originally develop but has licensed in most jurisdictions, eventually comes to market, the company could have a very popular product on its hands. Here's a look at what happened in its recent trial, and why investors reacted so cautiously after hearing about it. Image source: The Motley Fool.
CryptoAlerta — análise de criptomoedas e mercado em tempo real